U.S. Markets open in 5 hrs 31 mins

Update: United Therapeutics (NASDAQ:UTHR) Stock Gained 16% In The Last Five Years

Simply Wall St

United Therapeutics Corporation (NASDAQ:UTHR) shareholders might be concerned after seeing the share price drop 13% in the last week. But the silver lining is the stock is up over five years. However we are not very impressed because the share price is only up 16%, less than the market return of 56%.

See our latest analysis for United Therapeutics

To quote Buffett, ‘Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace…’ One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

Over half a decade, United Therapeutics managed to grow its earnings per share at 31% a year. This EPS growth is higher than the 3.1% average annual increase in the share price. So it seems the market isn’t so enthusiastic about the stock these days. This cautious sentiment is reflected in its (fairly low) P/E ratio of 8.17.

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

NasdaqGS:UTHR Past and Future Earnings, March 11th 2019

We know that United Therapeutics has improved its bottom line lately, but is it going to grow revenue? You could check out this free report showing analyst revenue forecasts.

A Different Perspective

While the broader market lost about 0.5% in the twelve months, United Therapeutics shareholders did even worse, losing 4.1%. Having said that, it’s inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Longer term investors wouldn’t be so upset, since they would have made 3.1%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. If you would like to research United Therapeutics in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

But note: United Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.